Des Crowley1, Walter Cullen2, Eamon Laird3, John S Lambert4, Tina Mc Hugh5, Carol Murphy4, Marie Claire Van Hout6. 1. Addiction Services HSE, Dublin7, Ireland. 2. University College Dublin, Dublin4, Ireland. 3. Trinity College Dublin, University College Dublin, Dublin2, Ireland. 4. Infectious Disease Department, Mater Hospital, Dublin7, Ireland. 5. Mater Hospital, Dublin, Ireland. 6. Public Health Institute, Liverpool John Moore's University, Liverpool, United Kingdom.
Abstract
BACKGROUND AND OBJECTIVES: Hepatitis C virus (HCV) infection is a major public health issue. There is substandard uptake in HCV assessment and treatment among people who inject drugs (PWID). Community fibroscanning is used to assess disease severity and target treatment. METHODS: A survey was administered to a cohort of chronically HCV infected patients attending a community fibroscanning clinic. Questions targeted diagnosis of HCV, suitability, willingness and barriers to engagement in treatment. Descriptive and regression analysis, with thematic analysis of open-ended data was conducted. RESULTS: There was high acceptance of community fibroscanning among this cohort with over 90% (68) attending. High levels of unemployment (90%) and homelessness (40%) were identified. Most patients were on methadone treatment and had been HCV infected for greater than 10 years with length of time since HCV diagnosis being significantly longer in patients with fibroscan scores > 8.5 kPa (P = 0.016). With each unit increase in methadone dose, the odds of the >8.5 fibroscan group increased by 5.2%. Patient identified barriers to engagement were alcohol and drug use, fear of HCV treatment and liver biopsy, imprisonment, distance to hospital and early morning appointments. CONCLUSION: The study highlights the usefulness of community fibroscanning. Identifying barriers to treatment in this cohort affords an opportunity to increase the treatment uptake. The availability of afternoon clinics and enhanced prison linkage are warranted.
BACKGROUND AND OBJECTIVES:Hepatitis C virus (HCV) infection is a major public health issue. There is substandard uptake in HCV assessment and treatment among people who inject drugs (PWID). Community fibroscanning is used to assess disease severity and target treatment. METHODS: A survey was administered to a cohort of chronically HCV infectedpatients attending a community fibroscanning clinic. Questions targeted diagnosis of HCV, suitability, willingness and barriers to engagement in treatment. Descriptive and regression analysis, with thematic analysis of open-ended data was conducted. RESULTS: There was high acceptance of community fibroscanning among this cohort with over 90% (68) attending. High levels of unemployment (90%) and homelessness (40%) were identified. Most patients were on methadone treatment and had been HCV infected for greater than 10 years with length of time since HCV diagnosis being significantly longer in patients with fibroscan scores > 8.5 kPa (P = 0.016). With each unit increase in methadone dose, the odds of the >8.5 fibroscan group increased by 5.2%. Patient identified barriers to engagement were alcohol and drug use, fear of HCV treatment and liver biopsy, imprisonment, distance to hospital and early morning appointments. CONCLUSION: The study highlights the usefulness of community fibroscanning. Identifying barriers to treatment in this cohort affords an opportunity to increase the treatment uptake. The availability of afternoon clinics and enhanced prison linkage are warranted.
Entities:
Keywords:
blood borne virus; drug users; fibroscan; hepatitis C virus; opiate substitution treatments
Authors: Paul K Nelson; Bradley M Mathers; Benjamin Cowie; Holly Hagan; Don Des Jarlais; Danielle Horyniak; Louisa Degenhardt Journal: Lancet Date: 2011-07-27 Impact factor: 79.321
Authors: Jason Grebely; Elizabeth Knight; Krista A Genoway; Mark Viljoen; Milan Khara; Doug Elliott; Lesley Gallagher; Michelle Storms; Jesse D Raffa; Stanley DeVlaming; Fiona Duncan; Brian Conway Journal: Eur J Gastroenterol Hepatol Date: 2010-03 Impact factor: 2.566
Authors: J Foucher; B Reiller; V Jullien; F Léal; E S di Cesare; W Merrouche; J-M Delile; V de Lédinghen Journal: J Viral Hepat Date: 2008-10-17 Impact factor: 3.728
Authors: A D Marshall; M Micallef; A Erratt; J Telenta; C Treloar; H Everingham; S C Jones; N Bath; D How-Chow; J Byrne; P Harvey; A Dunlop; M Jauncey; P Read; T Collie; G J Dore; J Grebely Journal: Int J Drug Policy Date: 2015-07-16
Authors: Shruti H Mehta; Becky L Genberg; Jacquie Astemborski; Ravi Kavasery; Gregory D Kirk; David Vlahov; Steffanie A Strathdee; David L Thomas Journal: J Community Health Date: 2008-06
Authors: Bernd Schulte; Christiane S Schmidt; Jakob Manthey; Lisa Strada; Stefan Christensen; Konrad Cimander; Herbert Görne; Pavel Khaykin; Norbert Scherbaum; Stefan Walcher; Stefan Mauss; Ingo Schäfer; Uwe Verthein; Jürgen Rehm; Jens Reimer Journal: Open Forum Infect Dis Date: 2020-08-13 Impact factor: 3.835
Authors: John S Lambert; Ross Murtagh; Dee Menezes; Austin O'Carroll; Carol Murphy; Walter Cullen; Tina McHugh; Gordana Avramovic; Willard Tinago; Marie Claire Van Hout Journal: BMC Infect Dis Date: 2019-02-07 Impact factor: 3.090
Authors: Geoff McCombe; Davina Swan; Eileen O'Connor; Gordana Avramovic; Peter Vickerman; Zoe Ward; Julian Surey; Juan Macías; John S Lambert; Walter Cullen Journal: JMIR Res Protoc Date: 2018-06-04